Paratek Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results - GlobeNewswire
Paratek Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results GlobeNewswire
... -- NUZYRA™ (omadacycline) Launched in the United States for the Treatment of CABP and ABSSSI --. -- New England Journal of Medicine Publishes Results ...
Comments
Post a Comment